Oncology Territory Manager, Solid Tumor (New Orleans)

Overview Menarini Stemline is hiring a Territory Manager, Breast Cancer/Solid Tumor. The Territory Manager is responsible for the sale and support of Stemline products to both existing and potential customers. The goals of this position are to acquire new customer business, increase market share through acquiring new accounts or expanding business in current customers, develop and encourage strong customer relationships, build brand loyalty, and provide customer satisfaction. Responsibilities Sell products to all potential and existing customers in designated territory to achieve overall territory revenue goals. Create strategic business plans for all key customer opportunities. Serve as a key business partner to clients and develop and maintain strong business relationships. Track, report and analyze territory opportunities with the Regional Sales Director (RSD) on a routine basis. Develop relationships with hospital HCPs through conversations, meetings, participation in conferences; makes new contacts within hospital and identifies key decision makers to facilitate future orders. Provides post-sales support for all territory business. Responds to customer needs and complaints regarding products and/or service by developing feasible solutions or working with other related personnel (e.g. clinical, marketing, etc.) to develop optimal solutions. Plan, prioritize, monitor, and track all sales cycle events utilizing CRM. Monitor and report customer satisfaction, support, or issues, to the Regional Sales Director. Monitor and update individual forecasted product volume data on a regular basis. Responsible for meeting individual sales/business targets as provided by Management. Attend all required Quality & Compliance training at the specified interval. Ability to work flexible hours and weekends to meet business and/or customer needs as directed. Participates in any and all work activities as assigned by management. Build Compliance into all aspects of their work by maintaining compliance to all Federal and State regulatory requirements. Qualifications Bachelor’s Degree. Minimum of 5 years pharmaceutical/biologic experience with at least 2 years within oncology. Breast Cancer experience preferred (ideally within past 7 years) Proven sales track record in the relevant product line. Must have a valid driver’s license. While performing the functions of this position, the individual must be able to frequently sit, stand, walk and drive a vehicle for an extended period of time. Travel is required to customer sites, including overnight travel that will vary depending on territory. Minimum expected travel is 50%+ Skills/Knowledge Clinical knowledge of product category with strong up to date understanding of the breast cancer treatment landscape. Solid understanding and application of business concepts, procedures and practices. Demonstrated ability to exceed business plan/quota, and able to develop sales plans for all required opportunities. Capable of managing time and resources within the assigned territory in conjunction with near-term plans to ensure the territory’s objectives are achieved. Ensure compliance with governmental and Stemline regulations. Maintaining honesty, integrity and excellent work ethic. Able to enhance teamwork within the region and maintain a collaborative relationship with all levels of the organization. Implement assigned operations within an established budget. Able to influence others and function effectively in a team environment. Excellent interpersonal, organizational, communication and listening skills. Entrepreneurial approach to market environments. Basic to intermediate Microsoft Office skills in Excel, Word and Outlook and CRMs. Base Salary Range of $180,000 - $220,000 (plus incentive compensation). Menarini Stemline offers generous compensation and benefits packages, including Fidelity 401(k) (with company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs. Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. The Company Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history. The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market. Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents. Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of hematological and solid tumors. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF). Additionally, Menarini received exclusive rights to commercialize Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines. Menarini entered into a global license agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023. It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business. #J-18808-Ljbffr Menarini Group